Current Opinion in Urology最新文献_第2页

Technological innovation and revolution with single-use digital flexible ureteroscopes: a review from section of EAU Endourology. 一次性数字化柔性输尿管镜的技术革新与革命：来自EAU输尿管学分会的综述。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-01-07 DOI: 10.1097/MOU.0000000000001260

Ali Talyshinskii, Lazaros Tzelves, Eugenio Ventimiglia, Steffi Kar Kai Yuen, Vineet Gauhar, Oliver Traxer, Bhaskar Somani

{"title":"Technological innovation and revolution with single-use digital flexible ureteroscopes: a review from section of EAU Endourology.","authors":"Ali Talyshinskii, Lazaros Tzelves, Eugenio Ventimiglia, Steffi Kar Kai Yuen, Vineet Gauhar, Oliver Traxer, Bhaskar Somani","doi":"10.1097/MOU.0000000000001260","DOIUrl":"10.1097/MOU.0000000000001260","url":null,"abstract":"Purpose of review: Numerous scope-related innovations have taken place in the field of endourology. The presented analytical review is aimed at studying the technical innovations of the single-use digital flexible ureteroscopes. In November 2024, a comprehensive search was done for information on latest disposable flexible digital ureteroscopes, as well as their various unique characteristics. A thorough examination was conducted for image qualities; sizes and channels; and deflection capabilities. Furthermore, supplementary features about the latest advances were assigned to a separate group including 'Unique' solutions. Using the last search query, various innovations in flexible ureteroscopy in general were also searched and sorted into appropriate groups.Recent findings: Modern single-use flexible digital ureteroscopes are characterized by advanced technologies for transmitting light and images, miniaturization, as well as by a number of unique solutions that were previously characteristic only of semi-rigid or fiberoptic endoscopes. These include features such as integrated buttons for data recording, self-locking mechanism, separate ports, rotating shaft, direct-in-scope suction, pressure monitoring, enhanced tip control and customizable settings.Summary: Since their introduction in urology, endoscopes have undergone many changes, as illustrated by the example of single-use flexible digital ureteroscopes. The imaging quality has improved, the dimensions of both the distal tip and shaft have decreased, with over 15 manufactures producing and distributing these scopes. A lot of new additional new features are likely to enhance the efficacy and safety of ureteroscopic procedures.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"360-367"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing clinical risk stratification of localized prostate cancer. 优化局限性前列腺癌的临床风险分层。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOU.0000000000001294

Vincent J Gnanapragasam

{"title":"Optimizing clinical risk stratification of localized prostate cancer.","authors":"Vincent J Gnanapragasam","doi":"10.1097/MOU.0000000000001294","DOIUrl":"10.1097/MOU.0000000000001294","url":null,"abstract":"Purpose of review: To review the current risk and prognostic stratification systems in localised prostate cancer. To explore some of the most promising adjuncts to clinical models and what the evidence has shown regarding their value.Recent findings: There are many new biomarker-based models seeking to improve, optimise or replace clinical models. There are promising data on the value of MRI, radiomics, genomic classifiers and most recently artificial intelligence tools in refining stratification. Despite the extensive literature however, there remains uncertainty on where in pathways they can provide the most benefit and whether a biomarker is most useful for prognosis or predictive use. Comparisons studies have also often overlooked the fact that clinical models have themselves evolved and the context of the baseline used in biomarker studies that have shown superiority have to be considered.Summary: For new biomarkers to be included in stratification models, well designed prospective clinical trials are needed. Until then, there needs to be caution in interpretation of their use for day-to-day decision making. It is critical that users balance any purported incremental value against the performance of the latest clinical classification and multivariate models especially as the latter are cost free and widely available.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"426-431"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measuring kidney stone volume - practical considerations and current evidence from the EAU endourology section. 测量肾结石体积-实际考虑和当前证据从EAU泌尿科。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-02-21 DOI: 10.1097/MOU.0000000000001271

Nico C Grossmann, Frederic Panthier, Luca Afferi, Panagiotis Kallidonis, Bhaskar K Somani

{"title":"Measuring kidney stone volume - practical considerations and current evidence from the EAU endourology section.","authors":"Nico C Grossmann, Frederic Panthier, Luca Afferi, Panagiotis Kallidonis, Bhaskar K Somani","doi":"10.1097/MOU.0000000000001271","DOIUrl":"10.1097/MOU.0000000000001271","url":null,"abstract":"Purpose of review: This narrative review provides an overview of the use, differences, and clinical impact of current methods for kidney stone volume assessment.Recent findings: The different approaches to volume measurement are based on noncontrast computed tomography (NCCT). While volume measurement using formulas is sufficient for smaller stones, it tends to overestimate volume for larger or irregularly shaped calculi. In contrast, software-based segmentation significantly improves accuracy and reproducibility, and artificial intelligence based volumetry additionally shows excellent agreement with reference standards while reducing observer variability and measurement time. Moreover, specific CT preparation protocols may further enhance image quality and thus improve measurement accuracy. Clinically, stone volume has proven to be a superior predictor of stone-related events during follow-up, spontaneous stone passage under conservative management, and stone-free rates after shockwave lithotripsy (SWL) and ureteroscopy (URS) compared to linear measurements.Summary: Although manual measurement remains practical, its accuracy diminishes for complex or larger stones. Software-based segmentation and volumetry offer higher precision and efficiency but require established standards and broader access to dedicated software for routine clinical use.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"323-330"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tissue-based gene expression testing in localized prostate cancer. 局部前列腺癌组织基因表达检测。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOU.0000000000001289

Nethusan Sivanesan, Gabriela M Diaz, Preston C Sprenkle

{"title":"Tissue-based gene expression testing in localized prostate cancer.","authors":"Nethusan Sivanesan, Gabriela M Diaz, Preston C Sprenkle","doi":"10.1097/MOU.0000000000001289","DOIUrl":"10.1097/MOU.0000000000001289","url":null,"abstract":"Purpose of review: This review presents the latest research in tissue-based genomic testing in localized prostate cancer (PCa). Here we explore the current and most commonly used genomic assays, their clinical applications, current challenges, and the future of genomic testing.Recent findings: The management of localized PCa has evolved with the integration of genomic assays, offering a more personalized approach to risk stratification and treatment decision-making. Traditional clinical markers such as PSA levels and Gleason scores are often insufficient in capturing clinically significant cancer due to disease heterogeneity.Summary: Tissue-based genomic tests, such as Decipher, Oncotype DX (GPS), and Prolaris, have emerged as prognostic tools for assessing tumor aggressiveness and metastatic potential. Current evidence supports Decipher's prognostic capabilities with studies demonstrating risk stratification while further research is needed for Prolaris and GPS to solidify their role in PCa risk stratification. These assays are intended to guide therapeutic choices, reducing overtreatment in low-risk cases while identifying high-risk patients who may benefit from more aggressive or definitive intervention. Despite growing clinical adoption, challenges such as cost, disparities in access, and variability in physician utilization still remain. Further prospective studies and randomized trials are required to optimize clinical implementation and validate the long-term impact of genomic testing on PCa outcomes.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"432-438"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

En bloc resection of large bladder tumor: is it feasible and reasonable? 膀胱大肿瘤整体切除是否可行、合理？

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-01-20 DOI: 10.1097/MOU.0000000000001265

Diana Babaevskaya, Andrey Morozov, Eddie Fridman, Larisa Tsoy, Shahrokh F Shariat, Yossef Molchanov, Maxim Yakimov, Eva Compérat, Thomas R W Herrmann, Dmitry Enikeev

{"title":"En bloc resection of large bladder tumor: is it feasible and reasonable?","authors":"Diana Babaevskaya, Andrey Morozov, Eddie Fridman, Larisa Tsoy, Shahrokh F Shariat, Yossef Molchanov, Maxim Yakimov, Eva Compérat, Thomas R W Herrmann, Dmitry Enikeev","doi":"10.1097/MOU.0000000000001265","DOIUrl":"10.1097/MOU.0000000000001265","url":null,"abstract":"Purpose of review: Transurethral resection of bladder tumor (TURBT) remains the basis of bladder tumor diagnosis and an effective means of treating nonmuscle invasive bladder cancer (NMIBC). There are several limitations to this procedure: TURBT may cause free floating of malignant cells in the bladder and as a result re-implantation and early recurrence. Also, it does not allow the pathologist to define the correct spatial orientation of the specimen. The development of en bloc resection of bladder tumor (ERBT) has helped overcome the abovementioned key disadvantages of TURBT. However, many urologists doubt whether this approach is feasible for treating larger tumors.Recent findings: In this review, it is shown that ERBT of large bladder tumor (>3 cm) is in fact a feasible and well tolerated method. Although there is a lack of comparative data proving its advantages over TURBT, en bloc in large tumor seems to result in better local cancer control (due to higher prevalence of detrusor specimen, lower need for re-TURBT), lower rate of relapse outside the resection area (due to lower risk of tumor cells circulation), and higher quality of pathology specimen.Summary: Despite the skepticism of some surgeons, potential difficulties caused by larger tumor size may be overcome easily, and most agree that tumor size should not limit the implementation of the method in their daily practice.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"385-389"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and BMI score as risk factors for urolithiasis: a systematic review over 30 years. 肥胖和BMI评分作为尿石症的危险因素：一项超过30年的系统回顾

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1097/MOU.0000000000001298

Megha Garg, Philip Joseph, Hans Johnson, Joseph Vayalil Lawrence, Bhaskar Somani, Bhavan Prasad Rai, Joe Philip

{"title":"Obesity and BMI score as risk factors for urolithiasis: a systematic review over 30 years.","authors":"Megha Garg, Philip Joseph, Hans Johnson, Joseph Vayalil Lawrence, Bhaskar Somani, Bhavan Prasad Rai, Joe Philip","doi":"10.1097/MOU.0000000000001298","DOIUrl":"10.1097/MOU.0000000000001298","url":null,"abstract":"Purpose of review: To examine association between high BMI, obesity, and kidney stone disease (KSD). For this, systematic review of empirical studies was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) guidelines. Cochrane Library, EMBASE, MEDLINE, CINAHL, AMED, Emcare, Clinicaltrials.gov, and WHO ICTRP were searched for English language population-based studies published from inception to October 2024, including adults aged at least 18 years reporting on high BMI, obesity and overweight, with incidence of KSD.Recent findings: The search identified 943 records, of which 15 relevant articles with 97 645 participants and 17 158 cases in total were enrolled in the narrative synthesis. A high heterogeneity and imbalance were observed among baseline distribution of cohorts in most studies. Thirteen studies provided comparative data on stone occurrence in obese and nonobese participants, and on per-patient analysis, three studies demonstrated a lower risk (RR < 1; 95% CI: 0.78-1.03), four studies a higher risk (RR>1; 95% CI: 0.77-2.32), and six studies depicted similar risk (RR = 1; 95% CI: 0.94-1.06) of stone occurrence between the two cohorts.Summary: Evidence in this study suggests an association between high BMI, being overweight, obesity, and increased risk of developing kidney stone disease. In the context of optimizing treatment, KSD should be considered a metabolic disease, with treatment to include dietary regimes, exercise intervention alongside pharmacotherapy to help reduce renal stone disease recurrence risk, alongside managing associated chronic diseases such as hypertension, type 2 diabetes mellitus, and coronary artery disease.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"338-346"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salvage treatment of local recurrence following radical and partial nephrectomy. 根治性和部分性肾切除术后局部复发的抢救治疗。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-04-04 DOI: 10.1097/MOU.0000000000001286

Davide Perri, Carlotta Palumbo, Alessandro Volpe

{"title":"Salvage treatment of local recurrence following radical and partial nephrectomy.","authors":"Davide Perri, Carlotta Palumbo, Alessandro Volpe","doi":"10.1097/MOU.0000000000001286","DOIUrl":"10.1097/MOU.0000000000001286","url":null,"abstract":"Purpose of review: Standardized definition of local recurrence after radical or partial nephrectomy is still lacking. Due to its rarity, data on natural history, oncological outcomes and prognostic factors are scarce and specific treatment recommendations cannot be made.Recent findings: Surgery is still the preferred option to treat a local recurrence of renal cell carcinoma, with favorable survival outcomes. However, nonsurgical options like thermal ablation techniques may represent a valid alternative mainly in patients where a nephron-sparing treatment is imperative. Systemic therapy seems to have a limited role in this setting.Summary: According to available data, surgical excision of local recurrence should be attempted whenever feasible. Alternatively, thermal ablation represents a reliable and repeatable option after partial nephrectomy, with low complication rate and good oncologic outcomes. However, the evidence comes mainly from limited, heterogeneous case series. Further high-quality studies are needed to properly define the most appropriate for each individual patient.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"481-488"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis. 放射配体和放射性同位素治疗前列腺癌的毒性：系统回顾和荟萃分析。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1097/MOU.0000000000001300

David Ventura, Benjamin Noto, Nadir Rodriguez Jauregui, Wolfgang Roll, Kambiz Rahbar

{"title":"Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis.","authors":"David Ventura, Benjamin Noto, Nadir Rodriguez Jauregui, Wolfgang Roll, Kambiz Rahbar","doi":"10.1097/MOU.0000000000001300","DOIUrl":"10.1097/MOU.0000000000001300","url":null,"abstract":"Purpose of review: This systematic review and meta-analysis investigate the toxicities of radioligand and radioisotope therapies - [ 177 Lu]lutetium-prostate-specific membrane antigen (PSMA) (Lu-PSMA), [ 225 Ac]actinium-PSMA (Ac-PSMA), and [ 223 Ra]radium-dichloride (223-Radium) - in metastatic prostate cancer. While previous studies have explored this topic, most failed to differentiate between treatment-emergent adverse events (TEAEs) and preexisting conditions, leading to inflated toxicity rates. By focusing exclusively on TEAEs, this study provides a more accurate and clinically relevant assessment.Recent findings: This meta-analysis of 65 studies including 8706 patients identified haematotoxicities as the most frequent TEAEs across all therapies, affecting 10-20% of patients. Fatigue is a common nonhematologic adverse event in all treatments. Low grade xerostomia is specifically associated with Lu-PSMA and Ac-PSMA therapies, occurring in 30% and 84% of patients, respectively, while 223-Radium is uniquely linked to an increased fracture risk. Severe toxicities (Common Terminology Criteria for Adverse Events ≥ 3) are rare across all therapies. By clearly distinguishing TEAEs from baseline conditions, this study addresses a gap in the existing literature.Summary: Severe TEAEs are uncommon across Lu-PSMA, Ac-PSMA, and 223-Radium therapies. Still, monitoring and managing specific toxicities to optimize the safety and tolerability of these therapies in clinical practice is mandatory, especially concerning xerostomia in Ac-PSMA therapy.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"472-480"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities of PARP inhibitors in genitourinary cancers. PARP抑制剂对泌尿生殖系统癌的毒性研究。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-05-07 DOI: 10.1097/MOU.0000000000001297

János Szalontai, Tibor Szarvas, Marcin Miszczyk, Péter Nyirády, Shahrokh F Shariat, Tamás Fazekas

{"title":"Toxicities of PARP inhibitors in genitourinary cancers.","authors":"János Szalontai, Tibor Szarvas, Marcin Miszczyk, Péter Nyirády, Shahrokh F Shariat, Tamás Fazekas","doi":"10.1097/MOU.0000000000001297","DOIUrl":"10.1097/MOU.0000000000001297","url":null,"abstract":"Purpose of review: Recent advancements in the understanding of the genetic background of genitourinary cancers allowed for a successful introduction of targeted antitumor agents to prostate cancer (PCa) treatment. Inhibitors of the poly ADP-ribose polymerase enzyme (PARPi) transformed the treatment landscape of metastatic prostate cancer, and being increasingly studied in earlier disease stages. However, they are associated with nonnegligible toxicity, therefore, we aimed to summarize their side-effect profile in patients with PCa.Recent findings: Hematologic toxicities, particularly anemia, thrombocytopenia, and neutropenia are among the most common and serious adverse events associated with PARPi, highlighting the need for regular blood count monitoring. Nonhematologic side effects, including fatigue, nausea, vomiting, diarrhea, and constipation, are common, and can be mitigated with supportive interventions like dietary modifications, antiemetics, or stool management techniques. Special attention should be given to patients with therapy-resistant or persistent cytopenia, in whom bone marrow biopsy should be considered, as it can indicate myelodysplastic syndrome and acute myeloid leukemia.Summary: PARP inhibitors represent a major advancement in the management of metastatic prostate cancer, offering a significant survival benefit in applicable cases. However, patients need to be carefully selected and informed, to allow for optimal balancing between the benefits and nonneglectable risks of severe toxicities. Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients' awareness about the possible side effects of PARPi.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"467-471"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prognostic role of prostate MRI in prostate cancer patients. 前列腺MRI在前列腺癌患者预后中的作用。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1097/MOU.0000000000001288

Paolo Zaurito, Armando Stabile, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia

{"title":"The prognostic role of prostate MRI in prostate cancer patients.","authors":"Paolo Zaurito, Armando Stabile, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia","doi":"10.1097/MOU.0000000000001288","DOIUrl":"10.1097/MOU.0000000000001288","url":null,"abstract":"Purpose of review: Multiparametric MRI (mpMRI) has been included in the diagnostic pathway of prostate cancer (PCa). However, the role of this imaging modality in predicting clinical outcomes after diagnosis has been poorly addressed so far. This review aims to summarize the most relevant updates on the prognostic role of mpMRI.Recent findings: Baseline mpMRI features help to predict adverse pathology at radical prostatectomy (RP) and grade reclassification during active surveillance. Parameters derived at prostate mpMRI such as PI-RADS score 4-5, the maximum diameter of the index lesion and the presence of extracapsular invasion/seminal vesicle invasion are among the strongest predictors of biochemical recurrence (BCR) for men treated with RP. mpMRI-based predictive models can achieve similar accuracy for BCR prediction when compared with validated models that relied on final pathology. Moreover, the use of mpMRI findings to predict disease recurrence after radiotherapy or focal therapy seems to optimize patient's risk stratification after treatment, ruling out disease recurrence.Summary: Clinicians should account for prostate mpMRI findings when predicting clinical outcomes in patients diagnosed with PCa.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"418-425"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0